Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
- Written by PR Newswire
- Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol)
- Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net and operating costs
- First quarter financial highlights...














